Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
N650302-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$120.90
|
|
|
N650302-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$190.90
|
|
|
N650302-25mg
|
25mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$380.90
|
|
|
N650302-50mg
|
50mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$610.90
|
|
|
N650302-100mg
|
100mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$980.90
|
|
| Specifications & Purity | ≥98% |
|---|---|
| Biochemical and Physiological Mechanisms | NDB is a selective human FXRα (hFXRα) antagonist that is effective in modulating transcription of FXRα downstream genes. NDB can be used in anti-diabetes research. |
| Storage Temp | Store at -20°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Product Description |
NDB is a selective human FXRα (hFXRα) antagonist that is effective in modulating transcription of FXRα downstream genes. NDB can be used in anti-diabetes research In Vitro NDB induces rearrangements of helix 11 (H11) and helix 12 (H12, AF-2) by forming a homodimer of hFXRα-LBD, totally different from the active conformation in monomer state. NDB (25 μM) effectively antagonizes the GW4064-stimulated FXR/RXR interaction and FXRα target gene expression in primary mouse hepatocytes, including the small heterodimer partner (SHP) and bile-salt export pump (BSEP). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo NDB (24 mg/kg; intraperitoneal injection; once a day; for 4 weeks) efficiently decreases the gene expressions of phosphoenolpyruvate carboxykinase (PEPCK), glucose 6-phosphatase (G6-pase), small heterodimer partner, and BSEP in db/db mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male C57BL/6J db/db mice (8 weeks of age) Dosage: 24 mg/kg Administration: Intraperitoneal injection; once a day; for 4 weeks Result: Decreased the gene expressions of PEPCK, G6-pase, small heterodimer partner, and BSEP. Form:Solid IC50& Target:Human FXRα (hFXRα) |
| Smiles | O=C(N(C1=CC=C(O)C(C(C)(C)C)=C1)CC2=CC=CC=C2)C3=C(Cl)C=C(N(C)C)C=C3Cl |
|---|---|
| Molecular Weight | 471.42 |
| Solubility | DMSO : 100 mg/mL (212.13 mM; Need ultrasonic) |
|---|